Increased microbial translocation in ≤180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age

Pediatric Infectious Disease Journal

Volumn 30, Issue 10, 2011, Pages 877-882

  Papasavvas, Emmanouil ^a   Azzoni, Livio ^a   Foulkes, Andrea ^b   Violari, Avy ^c   Cotton, Mark F ^d   Pistilli, Maxwell ^a   Reynolds, Griffin ^a   Yin, Xiangfan ^a   Glencross, Deborah K ^c   Stevens, Wendy S ^c   McIntyre, James A ^c,e   Montaner, Luis J ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e ANOVA HEALTH INSTITUTE   (South Africa)

Author keywords

HIV 1 infected infants; LPS; LPSbinding molecules; microbial translocation

Indexed keywords

CD4 ANTIGEN; ENDOTOXIN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

EID: 80052933872     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31821d141e     Document Type: Article

References (40)

1. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol. 2006;7:235-239.
2. Epple HJ, Schneider T, Troeger H, et al. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients. Gut. 2009;58:220-227.
3. Keating J, Bjarnason I, Somasundaram S, et al. Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhoea. Gut. 1995;37:623-629.
4. Leinert C, Stahl-Hennig C, Ecker A, et al. Microbial translocation in simian immunodeficiency virus (SIV)-infected rhesus monkeys (Macaca mulatta). J Med Primatol. 2010;39:243-251.
5. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE. 2008;3:e2516.
6. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-1371. (Pubitemid 44924494)
7. Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis. 2010;202:723-733.
8. Funderburg N, Luciano AA, Jiang W, et al. Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS ONE. 2008;3:e1915.
9. Lester RT, Yao XD, Ball TB, et al. HIV-1 RNA dysregulates the natural TLR response to subclinical endotoxemia in Kenyan female sex-workers. PLoS ONE. 2009;4:e5644.
10. Redd AD, Dabitao D, Bream JH, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci USA. 2009;106:6718-6723.
11. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376. (Pubitemid 37174535)
12. Caradonna L, Amati L, Magrone T, et al. Enteric bacteria, lipopolysaccha-rides and related cytokines in inflammatory bowel disease: biological and clinical significance. JEndotoxin Res. 2000;6:205-214.
13. Gregson JN, Steel A, Bower M, et al. Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1-infected individuals. AIDS. 2009;23:29-34.
14. Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS. 2008;22:2035-2038.
15. Papasavvas E, Pistilli M, Reynolds G, et al. Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS. 2009;23:369-375.
16. Hailman E, Lichenstein HS, Wurfel MM, et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med. 1994;179:269-277. (Pubitemid 24012992)
17. Frey EA, Miller DS, Jahr TG, et al. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med. 1992;176:1665-1671.
18. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res. 2005;11:225-229. (Pubitemid 41358857)
19. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249: 1431-1433.
20. Cohen IR, Norins LC. Natural human antibodies to gram-negative bacteria: immunoglobulins G, A, and M. Science. 1966;152:1257-1259.
21. Strutz F, Heller G, Krasemann K, et al. Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome. Intensive Care Med. 1999;25:435-444. (Pubitemid 29240437)
22. de Martino M, Tovo PA, Galli L, et al. Prognostic significance of immu-nologic changes in 675 infants perinatally exposed to human immunodeficiency virus. The Italian Register for Human Immunodeficiency Virus Infection in Children. JPediatr. 1991;119:702-709.
23. Luzuriaga K, Sullivan JL. Pediatric HIV-1 infection: advances and remaining challenges. AIDS Rev. 2002;4:21-26. (Pubitemid 34464231)
24. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233-2244.
25. Papasavvas E, Kostman JR, Thiel B, et al. HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J Clin Immunol. 2006;26:40-54. (Pubitemid 43115208)
26. Wallet MA, Rodriguez CA, Yin L, et al. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS. 2010;24:1281-1290.
27. Levy O. Impaired innate immunity at birth: deficiency of bactericidal/permeability-increasing protein (BPI) in the neutrophils of newborns. Pe-diatr Res. 2002;51:667-669. (Pubitemid 34547326)
28. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-1772. (Pubitemid 47025442)
29. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470-1481.
30. Moreno-Navarrete JM, Manco M, Ibanez J, et al. Metabolic endotoxemia and saturated fat contribute to circulating NGAL concentrations in subjects with insulin resistance. Int J Obes (Lond). 2010;34:240-249.
31. Townsend S, Caubilla Barron J, Loc-Carrillo C, et al. The presence of endotoxin in powdered infant formula milk and the influence of endotoxin and Enterobacter sakazakii on bacterial translocation in the infant rat. Food Microbiol. 2007;24:67-74. (Pubitemid 44163780)
32. Weaver LT, Arthur HM, Bunn JE, et al. Human milk IgA concentrations during the first year of lactation. Arch Dis Child. 1998;78:235-239. (Pubitemid 28176334)
33. Wold AE, Adlerberth I. Breast feeding and the intestinal microflora of the infant-implications for protection against infectious diseases. Adv Exp Med Biol. 2000;478:77-93. (Pubitemid 32174582)
34. Barclay GR. Endogenous endotoxin-core antibody (EndoCAb) as a marker of endotoxin exposure and a prognostic indicator: a review. Prog Clin Biol Res. 1995;392:263-272.
35. Kivilaakso E, Valtonen VV, Malkamaki M, et al. Endotoxaemia and acute pancreatitis: correlation between the severity of the disease and the anti-enterobacterial common antigen antibody titre. Gut. 1984;25: 1065-1070. (Pubitemid 14002120)
36. Windsor JA, Fearon KC, Ross JA, et al. Role of serum endotoxin and antiendotoxin core antibody levels in predicting the development of multiple organ failure in acute pancreatitis. Br J Surg. 1993;80:1042-1046. (Pubitemid 23261594)
37. Lien E, Aukrust P, Sundan A, et al. Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood. 1998;92: 2084-2092. (Pubitemid 28446698)
38. Nockher WA, Bergmann L, Scherberich JE. Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients. Clin Exp Immunol. 1994;98:369-374. (Pubitemid 24374718)
39. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203: 780-790.
40. Titanji K, De Milito A, Cagigi A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood. 2006;108:1580-1587 (Pubitemid 44316125)